30 years. 30 patents. 250+ life-science companies.
What’s blocking your path to funding, adoption, and revenue?
The Funding & Revenue Pathway Assessment pinpoints exactly what’s stalling your company, then hands you a roadmap you can act on. A deep working assessment with Michele Zoromski, built on 30 years and 250+ life-science companies. For physician-led companies.
For physician entrepreneurs
You built the practice. We’ll build the company.
Most physician founders don’t fail because the science is weak. They get stuck on what comes next: funding strategy, regulatory sequencing, reimbursement, the path to adoption, building a company while still seeing patients.
The FRPA names exactly what’s blocking your path and the specific remedies that move you forward.
Where most life-science companies stall
The commercialization valley.
Research resources sit on one cliff. Commercial resources sit on the other. The valley between them is where most physician-led life-science companies lose momentum: running out of runway, raising the wrong way, or building a product that no one’s ready to pay for.
The FRPA finds the bridge, across funding, regulatory, reimbursement, target market, and the path to first revenue.
What the FRPA delivers
A deep assessment. A roadmap you can act on.
A full commercialization assessment
Together we map the gaps across regulatory, reimbursement, commercialization, and go-to-market, using your real pitch deck, funding status, and the decisions you’re trying to make next.
Your written gap-and-remedy roadmap
Delivered within 3-4 weeks. Prioritized findings, specific remedies, and the moves worth making next, in order. Built to act on, not slide-ware.
A walk-through call
We walk through the roadmap together once you’ve read it, focused on the two or three findings that need the most context to act on.
The full picture
Commercialization isn’t one thing. It’s seven, all connected.
Regulatory. Intellectual property. Reimbursement. Strategic partners. Clinical. Marketing and sales. Funding. Each one shapes the others, and a gap in any one of them stalls the whole company.
The FRPA assesses your position across all seven, then prioritizes which two or three you need to act on first.
The advisor
Michele Zoromski
30 years. 30 patents. 250+ life-science companies.
- 250+ life-sciences companies guided – start-ups to global leaders: NIH, Medtronic, Boston Scientific, Janssen, Vistakon, Beckman Coulter, Endoshape, Preventice, Cognition, Logic PD, Jaan Biotherapeutics.
- Inventor’s track record – 30+ granted patents (plus pending applications) across stents, embolic filters, and medical-device materials (Boston Scientific, W. L. Gore).
- End-to-end commercial expertise – clinical, regulatory, reimbursement, business model, target market, marketing, sales, funding, and strategic partnerships.
- My passion: the bedside, not the bench. Getting technology into physicians’ hands, where it serves patients.
m.zoro Consulting is a woman-majority owned business.
What clients say
“Michele’s team efficiently gathered details on our company and translated the data into highly valuable actionable intelligence in a concise format. Highly recommended!”
B.B., Founder & CEO, Quench Medical
Two ways to engage
Start where you are.
Talk first
A free 20-minute Discovery Call to see if the FRPA is the right next step. No commitment, no pitch.
Free | 20 min
Book the FRPA
A full assessment of what’s blocking your path to funding, adoption, and revenue, delivered as a written roadmap in 3-4 weeks. Pay to reserve your slot, and we start as soon as you book.
$2,500
You built the practice. We’ll build the company.
m.zoro Consulting | mzoro.com | 1-855-FRPA-FIX (1-855-377-2349)
Confidential and proprietary.